MMP2 and glioblastoma: A recently developed MMP-2-responsive nanoplatform (S-biAb/dEGCG@NPs) substantially increases intratumoral accumulation and therapeutic efficacy of antibodies through multimodal synergy, offering a forward-looking solution to delivery barriers in GBM therapy 130.